Washington, D.C. 20549


Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 7, 2020

(Exact Name of Registrant as Specified in its Charter)
(State or Other Jurisdiction of Incorporation or Organization)(Commission File No.)(I.R.S. Employer Identification No.)

1020 Stony Hill Road, Suite 300
Yardley, Pennsylvania 19067
(Address of principal executive offices and zip code)

(267) 364-3500
(Registrant’s telephone number, including area code)
(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common stock, par value $0.001 per shareOPTNNasdaq Global Select Market

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers.

Effective as November 7, 2020, Mr. Sriram Venkataraman resigned from the Company’s Board of Directors (“Board”) and as a member of the Board’s Compensation and Nominating & Corporate Governance committees, and Mr. Robert O’Neil resigned from the Board. Mr. Venkataraman and Mr. O’Neil were the designees to the Board pursuant to the Company’s Stockholders’ Agreement, dated as of October 2, 2017, with Avista Capital Partners II, LP, Avista Capital Partners (Offshore) II, LP and Avista Capital Partners (Offshore) II-A, LP (collectively, “Avista”). Mr. Venkataraman’s and Mr. O’Neil’s resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices. The Company thanks Mr. Venkataraman and Mr. O’Neil for their service and valuable contributions to the Company.

Effective as of November 10, 2020, Ms. Catherine E. Owen was appointed to the Board’s Compensation Committee to fill the vacancy created by Mr. Venkataraman’s resignation and Mr. Joseph Scodari, who is already a member of the Compensation Committee, was appointed Chairman of the Compensation Committee. Further, effective as of November 10, 2020, Mr. Scodari was appointed to fill the vacancy on the Board’s Audit Committee. The Audit Committee now has three independent director members in compliance with Nasdaq Listing Rule 5605(c)(2)(A).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
  OptiNose, Inc.
By: /s/ Keith A. Goldan
  Keith A. Goldan
  Chief Financial Officer
Date: November 12, 2020